Medical AI device company AIDOT announced on the 30th that it has successfully entered the Japanese market with “GIGA dot AI,” an AI-based gastroscopy screening solution jointly developed with Hallym University Chuncheon Sacred Heart Hospital.

AIDOT’s Japanese partner explained that it selected GIGA dot AI because, when physicians use AI assistance for diagnostic support during gastroscopy screening, the solution is more optimized than any AI gastroscopy solution developed in Japan.

GIGA dot AI has received MFDS clinical trial plan approval in Korea, and a clinical trial is currently underway led by Professor Bang Chang-seok of the Division of Gastroenterology at Hallym University Chuncheon Sacred Heart Hospital, the joint research institution.

During gastroscopy procedures, GIGA dot AI classifies images into six severity categories: Non-neoplasm, LGD, HGD, EGC (M), EGC (SM), and AGC, and the AI provides real-time guidance by indicating the location of suspected lesions with sound alerts and a detection box.

According to the company’s internal clinical performance verification, the overall sensitivity and specificity—reflecting sensitivity and specificity by severity—were 91.48% and 92.13%, respectively.

A company representative stated that additional contract discussions to ensure continued solution supply in the Japanese market have also been completed, and added that based on this Japanese market entry reference, AIDOT plans to pursue further expansion through close discussions with partners in Europe and India, while continuously advancing the solution to build global competitiveness.

Published: January 30, 2023 / Korea Economic TV / Senior Reporter Yang Jae-jun